181 related articles for article (PubMed ID: 8648363)
41. [Clinical study of high-dose chemotherapy with peripheral blood stem cell transplantation for poor-risk germ cell tumor].
Okamura K; Yuba H; Mizutani K; Gotoh M; Ono Y; Ohshima S; Naoe T
Hinyokika Kiyo; 1999 Nov; 45(11):793-8. PubMed ID: 10637746
[TBL] [Abstract][Full Text] [Related]
42. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
[TBL] [Abstract][Full Text] [Related]
43. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
Bokemeyer C; Kollmannsberger C; Meisner C; Harstrick A; Beyer J; Metzner B; Hartmann JT; Schmoll HJ; Einhorn L; Kanz L; Nichols C
J Clin Oncol; 1999 Nov; 17(11):3450-6. PubMed ID: 10550141
[TBL] [Abstract][Full Text] [Related]
44. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
Bajorin DF; Sarosdy MF; Pfister DG; Mazumdar M; Motzer RJ; Scher HI; Geller NL; Fair WR; Herr H; Sogani P
J Clin Oncol; 1993 Apr; 11(4):598-606. PubMed ID: 8386751
[TBL] [Abstract][Full Text] [Related]
45. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
46. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W
Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
[TBL] [Abstract][Full Text] [Related]
47. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
48. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated.
Motzer RJ; Gulati SC; Crown JP; Weisen S; Doherty M; Herr H; Fair W; Sheinfeld J; Sogani P; Russo P
Cancer; 1992 Jan; 69(2):550-6. PubMed ID: 1309436
[TBL] [Abstract][Full Text] [Related]
49. Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: a randomized comparison.
Bosl GJ; Bajorin DF
Semin Oncol; 1994 Oct; 21(5 Suppl 12):61-4. PubMed ID: 7992068
[TBL] [Abstract][Full Text] [Related]
50. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
[TBL] [Abstract][Full Text] [Related]
51. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.
Xiao H; Mazumdar M; Bajorin DF; Sarosdy M; Vlamis V; Spicer J; Ferrara J; Bosl GJ; Motzer RJ
J Clin Oncol; 1997 Jul; 15(7):2553-8. PubMed ID: 9215824
[TBL] [Abstract][Full Text] [Related]
52. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
53. Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
Culine S; Theodore C; Farhat F; Bekradda M; Terrier-Lacombe MJ; Droz JP
J Surg Oncol; 1996 Mar; 61(3):195-8. PubMed ID: 8637206
[TBL] [Abstract][Full Text] [Related]
54. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity.
Decatris MP; Wilkinson PM; Welch RS; Metzner M; Morgenstern GR; Dougall M
Ann Oncol; 2000 Apr; 11(4):427-34. PubMed ID: 10847461
[TBL] [Abstract][Full Text] [Related]
55. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
[TBL] [Abstract][Full Text] [Related]
56. Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol.
Kellie SJ; Boyce H; Dunkel IJ; Diez B; Rosenblum M; Brualdi L; Finlay JL
J Clin Oncol; 2004 Mar; 22(5):846-53. PubMed ID: 14990640
[TBL] [Abstract][Full Text] [Related]
57. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
[TBL] [Abstract][Full Text] [Related]
58. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
59. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
[TBL] [Abstract][Full Text] [Related]
60. Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors.
Buckner JC; Peethambaram PP; Smithson WA; Groover RV; Schomberg PJ; Kimmel DW; Raffel C; O'Fallon JR; Neglia J; Shaw EG
J Clin Oncol; 1999 Mar; 17(3):933-40. PubMed ID: 10071287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
